MoonLake Immunotherapeutics (Group)

https://www.moonlaketx.com

MoonLake Immunotherapeutics AG, founded in 2021, is a clinical-stage biopharmaceutical company leveraging Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics has a portfolio of therapeutic programs based on Sonelokimab (M1095/ALX-0761), a biologic molecule potentially capable of driving disease modification in dermatology and rheumatology patients. *

	Start	2021-01-01 established (approx)
	Today	MoonLake Immunotherapeutics AG (Nasdaq: MLTX)
	Industry	drug development

	Street	29 Dorfstr.
	City	6300 Zug ZG
		Address record changed: 2024-04-11

Basic data	Employees	B: 11 to 50 (2023-12-31)
	Currency	USD
	Profit	-44,079,117 (2023-12-31)
	Cash	511,008,237 (2023-12-31)

		* Document for »About Section«: MoonLake Immunotherapeutics AG. (7/1/21). "Press Release: MoonLake Immunotherapeutics Appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO". Zug.

		Record changed: 2024-12-29

Picture Berlin Partner Life Sciences Report 2024-2025 650x200px

More documents for MoonLake Immunotherapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)